SCHEDULE: Ameriprise, Columbia Management Disclose 8.4% Pasithea Stake

Ameriprise Financial, Inc. and its subsidiary Columbia Management Investment Advisers, LLC have disclosed a beneficial ownership of 8.4% of Pasithea Therapeutics Corp. common stock.

Summary

• Ameriprise Financial, Inc. and its subsidiary, Columbia Management Investment Advisers, LLC, collectively reported beneficial ownership of 1,930,128 shares of Pasithea Therapeutics Corp. common stock.
• This represents 8.4% of the total outstanding common stock of Pasithea Therapeutics Corp.
• The shares are held with shared voting power and shared dispositive power by both reporting entities.
• The filing was made under Rule 13d-1(b), indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive signal, as it confirms a significant institutional investor's stake, which can be interpreted as a vote of confidence, though the filing itself is purely informational.

Positives

• A significant institutional investor, Ameriprise Financial, Inc., through its subsidiary Columbia Management Investment Advisers, LLC, holds a notable stake in Pasithea Therapeutics Corp., potentially signaling confidence in the company.

Negatives

• The filing itself does not contain any negative information regarding Pasithea Therapeutics Corp.'s performance or outlook.

Risks

• The filing does not detail specific risks related to Pasithea Therapeutics Corp.'s operations or financial health.

Industry Context

StockSavvy.ai notes that Schedule 13G filings provide transparency into significant institutional ownership, indicating that large investment firms like Ameriprise Financial and Columbia Management Investment Advisers have taken a substantial position in Pasithea Therapeutics Corp. This type of disclosure is common for institutional investors holding over 5% of a company's stock for investment purposes, rather than seeking control.

Stakeholder Impact

• Shareholders: Increased transparency regarding institutional ownership, potentially offering a minor boost to investor confidence by showing a large firm's stake.

Key Dates

Keywords

Pasithea Therapeutics, Ameriprise Financial, Columbia Management, Common Stock, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Ownership, Investment Adviser, Biotechnology